SEPTInvestingStart Free

LAB 424B3: Acquisition

Standard BioTools Inc.

Filed with the SEC on · accession 0001140361-26-040401

LAB filed a 424B3 (prospectus (offering)) with the SEC on Oct 21, 2026. Standard BioTools Inc. filed a proxy statement/prospectus for a special meeting to approve an all-stock merger with Treeline Biosciences, Inc., in which Treeline will become a wholly owned subsidiary of Standard BioTools. The stock moved +2.0% by the first close after the filing.

Summary of the filing

Standard BioTools Inc. filed a proxy statement/prospectus for a special meeting to approve an all-stock merger with Treeline Biosciences, Inc., in which Treeline will become a wholly owned subsidiary of Standard BioTools. The combined company will be renamed Treeline Biosciences, Inc., and a reverse stock split will be effected; former Standard BioTools stockholders are expected to own approximately 16% of the combined company, while former Treeline stockholders will own approximately 84%.

For details, click here →How to read a 424B3 →

Key details

Treeline equity value$2.5B
Standard BioTools equity value$460.0M
Parent Net Cash threshold low$449.0M
Parent Net Cash threshold high$451.0M
Maximum shares of Standard BioTools common stock registered$537.7M
AcquirerStandard BioTools Inc.
TargetTreeline Biosciences, Inc.
Merger subsidiarySiri Merger Sub, Inc.

How LAB stock reacted

Close before

$0.64

Oct 20, 2026

First close after

+1.99%

$0.65

5 trading days

-3.33%

$0.62

Since filing

-0.20%

$0.64

✦ Ask GOAX AI about this filing — what it means for LAB, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for LAB?

Click here

Frequently asked questions

What did LAB file with the SEC on Oct 21, 2026?

LAB filed a 424B3 (Acquisition). Standard BioTools Inc. filed a proxy statement/prospectus for a special meeting to approve an all-stock merger with Treeline Biosciences, Inc., in which Treeline will become a wholly owned subsidiary of Standard BioTools. The combined company will be renamed Treeline Biosciences, Inc., and a reverse stock split will be effected; former Standard BioTools stockholders are expected to own approximately 16% of the combined company, while former Treeline stockholders will own approximately 84%.

What does a acquisition mean for LAB stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 424B3?

The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B3 (prospectus (offering)): The final terms of an offering of shares or bonds.

How did LAB stock react to this filing?

LAB closed at $0.64 before the filing and $0.65 on Oct 21, 2026 (+1.99%). Five trading days later: $0.62 (-3.33%).

Other LAB SEC filings

Get alerts when LAB files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
LAB overviewLAB analysisLAB newsLatest SEC filings